SubHero Banner

Retevmo® (selpercatinib) – New indication

September 21, 2022 - Eli Lilly announced the FDA approval of Retevmo (selpercatinib), for the treatment of adult patients with locally advanced or metastatic solid tumors with a rearranged during transfection (RET) gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options.

Download PDF